Factors associated with medication adherence and persistence of treatment for hypertension in a Medicaid population

Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin‐Converting Enzyme Inhibitors: The Prospective EARLY Registry

“…1,9,10 Several studies suggest that targeting the RAS with ACE inhibitors or ARBs is associated with the greatest antihypertensive therapy persistence. 6,[10][11][12] In the present study, a similar proportion of newly diagnosed patients and those with established hypertension persisted with the initially prescribed therapy during the 12-month follow-up.…”

“…Indeed, it has been reported that only 25% of patients with newly initiated treatment redeem their first prescription, and among those who do, the rate of discontinuation during the first year is approximately 50%. [6][7][8] Selection of the optimal first-line antihypertensive regimen with respect to efficacy and tolerability is known to positively influence both treatment compliance and persistence. 1,9,10 Several studies suggest that targeting the RAS with ACE inhibitors or ARBs is associated with the greatest antihypertensive therapy persistence.…”

Comparative effectiveness of antihypertensive drugs in nondiabetic patients with hypertension: A population‐based study

“…In a cohort of Medicaid beneficiaries, after 6 months of therapy, those using diuretics had a 2-fold higher likelihood of discontinuing therapy compared with patients using CCBs or ACEIs. 19 Elderly patients from the province of Ontario, Canada, initially prescribed diuretics were less likely to persist on therapy compared with those taking ACEIs, ARBs, or CCBs.…”

Understanding Reasons for Nonadherence to Medications in a Medicare Part D Beneficiary Sample

“…This sample population reported nonadherence to newly prescribed medications that parallel findings from other published studies. 39,40 Yet, pharmacists are in a unique position to help these patients overcome adherence-related barriers to improve health-related outcomes.…”